Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, phase 3 study of the efficacy and safety of HZT-501 in subjects requiring NSAID treatment

X
Trial Profile

A randomized, double-blind, phase 3 study of the efficacy and safety of HZT-501 in subjects requiring NSAID treatment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Dec 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibuprofen/famotidine (Primary) ; Ibuprofen
  • Indications Arthritis; Duodenal ulcer; Gastric ulcer; Musculoskeletal pain; NSAID-induced ulcer
  • Focus Registrational; Therapeutic Use
  • Acronyms REDUCE-1
  • Sponsors Horizon Pharma
  • Most Recent Events

    • 20 Dec 2011 Pooled results from REDUCE-1 and REDUCE-2 published in the American Journal of Gastroenterology.
    • 25 Apr 2011 Based on the results of this and the REDUCE-2 trial, the US FDA approved ibuprofen/famotidine for the reduction of the risk of development of upper gastrointestinal ulcers in patients with rheumatoid arthritis or osteoarthritis.
    • 03 Nov 2010 Results will be presented at the 74th Annual Scientific Meeting of the American College of Rheumatology and the 45th Annual Meeting of the Association of Rheumatology and Health Professionals, according to an Horizon Pharma media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top